Ozanimod Shows Real-World Effectiveness in UC, but Week-48 Results Need Cautious Interpretation: Medicina | September 2026

Introduction

Ozanimod is an oral sphingosine-1-phosphate (S1P) receptor modulator approved for moderate-to-severe ulcerative colitis (UC), with efficacy established in the phase 3 True North program. However, real-world evidence remains limited, particularly regarding longer-term effectiveness, treatment persistence, and outcomes after prior biologic exposure.

This Pan-Hellenic multicenter study evaluated ozanimod in routine clinical practice across tertiary IBD centres in Greece.

Why was this study needed?

Clinical trial populations may not fully reflect patients encountered in routine IBD practice.

Real-world data for ozanimod remain relatively limited.

Effectiveness after previous biologic therapy is particularly relevant when positioning ozanimod within the UC treatment sequence.

Longer-term treatment persistence and reasons for discontinuation are important beyond induction response.

Real-world safety data can complement the established randomized trial experience.

Key Findings

At week 12, among 62 evaluable patients, 77% achieved clinical response and 71% clinical remission.

Week-48 observed-case results appeared particularly strong: 96% clinical response and 85% remission among 26 evaluable patients.

Overall prior biologic exposure did not significantly reduce treatment persistence.

Previous vedolizumab exposure was associated with greater treatment discontinuation, with an adjusted ~3-fold higher hazard of stopping ozanimod.

Adverse events were reported in 14% of patients, supporting a generally favorable real-world safety profile.

Bottom Line

Ozanimod appears to be an effective and generally well-tolerated oral treatment for UC in real-world practice, including in some biologic-experienced patients. However, the impressive observed-case week-48 remission rate should not be interpreted as an 85% real-world remission rate, because of substantial attrition; the treatment-failure analysis suggests a more realistic remission estimate of approximately 46%.

The association between previous vedolizumab exposure and ozanimod discontinuation is interesting but hypothesis-generating rather than practice-changing, given the small retrospective cohort. Overall, this study supports current use of ozanimod rather than changing its position in the UC treatment algorithm.